All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
The study demonstrates that repeated treatment with its lead compound Cdr132 L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CK-3772271
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-271
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
CK-271 is a second cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): JK07
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Carlyle
Deal Size: $260.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 01, 2020
Details:
Salubris has developed a comprehensive innovative pipeline in the treatment of chronic diseases, including JK07, an innovative biologic drug treating heart failure which has filed for clinical trial approvals in both China and the United States.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ARO-APOC3
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ARO-APOC3
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Presentation to showcase Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 being developed as a treatment for mixed dyslipidemias.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MRG-110
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MRG-110
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
Data demonstrate that a single systemic dose of MRG-110 reduced detectable miR-92a levels in the peripheral blood of humans and led to the regulation of several well established miR-92a target genes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SST-5058
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SST-5058
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
STT-5058 is a monoclonal antibody that targets the lipoprotein ApoC3 and is being developed in collaboration with Novo Nordisk.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Redasemtide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: S-005151
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: StemRIM
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 30, 2020
Details:
The companies have entered a licensing agreement for S-005151 [Generic name: Redasemtide] to conduct investigator-initiated clinical studies targeting new indications in the future.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI1029539
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
The clinical study was aimed at evaluating the safety, tolerability, pharmacokinetic and pharmacodynamic properties of OX-MPI to healthy subjects after single and multiple ascending dosages.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Small interfering RNA
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: $2,080.0 million Upfront Cash: $60.0 million
Deal Type: Collaboration March 26, 2020
Details:
Companies working together to deliver siRNA molecules to liver, breast, lung and other tissues. Within the first three years of the agreement the parties anticipate starting work on five targets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Allogeneic iPSC-derived cardiomyocytes
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Itochu Chemical Frontier
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 10, 2020
Details:
Through this partnership, Heartseed will leverage ICF’s global network of academia and research institutions to explore iPS-Cell and Cardiomyocyte-related business opportunities.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
